Lloyd Diamond has been appointed Chief Executive Officer at Nitinotes effective immediately. (Nitinotes are the developers of EndoZip™, a fully automated endoscopic suturing system aimed at treating obesity).
Lloyd Diamond brings more than 30 years of leadership in the medical device industry, having spearheaded significant advancements in orthopedics, endoscopic, and general surgical devices. Most recently, he served as CEO of Pixium Vision S.A., where he led the development of groundbreaking bionic vision systems and strategic partnerships.
John Barr, Chairman of the Board:
“We are thrilled to welcome Lloyd to lead Nitinotes into its next chapter of innovation and growth. Building upon the foundation established and the exceptional achievements attained, his extensive experience in medical technologies positions him as an outstanding leader to advance our future initiatives.”
Lloyd Diamond succeeds Raz Bar-On, who will continue as GM of Nitinotes Israel, overseeing operations, R&D, and regulatory functions.
Lloyd Diamond said:
“I am honored to join Nitinotes at this pivotal time. With obesity rates rising worldwide and over 1 billion people affected, EndoZip™ provides a critical solution to a significant global health challenge. I look forward to working with the talented team to bring this solution to more patients and healthcare providers worldwide.”
As Nitinotes prepares for pivotal trials in the U.S., the company is also enhancing its operational capabilities to meet global demand and regulatory milestones, specifically focusing on the imminent CE mark approval and the European commercial launch.
About Nitinotes: A Leader in Innovative Obesity Treatment
Nitinotes is a pioneer in medical technology, focusing on an innovative solution for obesity treatment. The company’s flagship product, EndoZip™, offers a minimally invasive approach for obesity class I & II patients, ensuring consistent, safe suturing with the press of a button, representing a significant advancement in the field.
